Sep 8, 2026
In this
episode of BioTalk with Rich Bendis, Subin Baral, Partner at Ernst
& Young LLP and EY-Parthenon Global Life Sciences Deals Leader,
joins the conversation to discuss the changing life sciences
dealmaking environment and what it means for companies, investors,
and regional innovation
ecosystems.
Subin shares how life sciences companies are shifting from
defensive portfolio management toward acquiring earlier-stage
assets, technologies, and capabilities that can support long-term
growth. He discusses why buyers are looking earlier in the
development cycle, what makes an asset attractive in the current
market, and why differentiated science, strong data, and flexible
deal structures matter more than
ever.
The conversation also explores the current M&A environment,
including EY’s view that life sciences M&A activity has
accelerated significantly, with stronger activity across both
biopharma and MedTech. Subin touches on the broader mix of buyers
entering the market, the role of mid-sized companies, and how areas
such as oncology, immunology, neuroscience, cell and gene therapy,
ADCs, bispecifics, AI, data, and quantum may shape future deal
activity.
Rich and Subin also discuss the growing role of China in global
life sciences innovation, the challenges facing early-stage
companies as funding remains difficult, and how startups can think
about partnerships, capital access, and strategic flexibility in a
more disciplined
market.
The episode also looks at what these trends mean for regions like
the BioHealth Capital Region, including how emerging ecosystems can
build visibility, strengthen networks, support differentiated
technologies, and position companies for future capital,
partnerships, and deal
activity.
Editing and post-production work for this episode was provided by
The Podcast
Consultant.
Subin is a partner at Ernst & Young LLP and the EY-Parthenon Global
Life Sciences Deals Leader. He has more than a decade of
transaction experience, helping life sciences companies with
transformational transactions. Subin has extensive global
experience serving as a buy- and sell-side transaction advisor for
Fortune 500 companies, including in corporate and private equity.
His experience includes working with companies in the
pharmaceutical, medical device and biotechnology subsectors. Subin
focuses on acquisitions, carve-outs, spin-offs and initial public
offerings and works with companies at all stages of maturity, from
startups to public companies. He frequently speaks at life sciences
events about sector trends and acquisitions and divestitures
topics. He received his Master of Commerce from Macquarie
University in Sydney, Australia. He is a chartered accountant from
the Institute of Chartered Accountants of Australia and New
Zealand.